MORE►
biotech
The Colossal Foundation is partnering with the University of Tasmania on an initiative to fight a facial cancer that has reduced the wild population of Tasmanian devils by 80% since the 1990s. [Photo: Colossal Foundation]
Colossal Foundation Partners with the University of Tasmania to ‘Give Tasmanian Devils a Fighting Chance’
by Sandra Engelland | Jul 7, 2026
By using a vaccine and gene editing, the partners aim to fight a lethal cancer that has reduced the wild population of Tasmanian devils by 80% since the 1990s.
by Lauren Lawley Head |
Jul 6, 2026
“We are giving physicians and patients a powerful new tool to help identify cancer earlier and support more informed clinical decisions,” CEO David Dean Halbert says of Caris Detect.
MORE►
by Maddie Preston |
Feb 3, 2026
A UT Dallas study supports Allen-based EnLiSense’s approach to circadian health monitoring, via a wearable that directly measures biochemical markers tied to wakefulness and sleep.
MORE►
by Sandra Engelland |
Dec 30, 2025
The Fort Worth oncology company tapped former Salarius Pharmaceuticals CEO David Arthur to lead its push toward commercialization, including a planned IND for a rare pediatric brain cancer program.
MORE►
Cait Brumme CEO of MassChallenge. [Photo: MassChallenge]
The Last Word: MassChallenge CEO on INNOVATE ’25 and Looking Ahead at Forces Shaping Economies
by Quincy Preston | Nov 5, 2025
Cait Brumme says the event at Dallas' Pegasus Park on Nov. 6 will explore the technologies and economic forces defining the future for entrepreneurs and innovators.
MORE►
by Quincy Preston |
Nov 4, 2025
The de-extinction startup is adding more than two decades of commercial cloning expertise to its portfolio with its first acquisition.
Days before the announcement, CEO Ben Lamm laid out his playbook at Venture Dallas 2025: run toward critics, treat promises to middle-America classrooms as seriously as commitments to investors—and spin out businesses worth more than $100 million.
MORE►
by David Seeley |
Oct 23, 2025
The Palo Alto-based company's new Dallas facility is its first dedicated U.S. laboratory, and will serve as its U.S. clinical operations headquarters. Overture's AI-driven IVF technology gives fertility teams "objective data to inform embryo selection without a biopsy," the company said, "allowing clinics to process three times the number of procedures without adding staff."
MORE►
by Quincy Preston |
Oct 14, 2025
The North Texas biotech, which uses AI to accelerate cancer drug development, received FDA feedback to advance a new clinical study targeting a rare childhood brain tumor.
MORE►
John Crowley, CEO of the Biotechnology Innovation Organization; Texas State Sen. Tan Parker; and Victoria Ford, CEO of the Texas Healthcare and Bioscience Institute, were among the voices shaping the conversation at the 2025 BioNTX iC3 Summit in Dallas. [Photos: Courtesy/BioNTX]
‘The Model is Broken’: From North Texas, a National Call to Action for Biotech’s Future
by Glenn Hunter | Sep 24, 2025
At Dallas’ iC3 Summit, leaders from Texas and across the U.S. pointed to AI, new state initiatives like Proposition 14, and potential federal reforms as keys to speeding innovation and keeping America competitive in life sciences.
MORE►
by Lance Murray |
Aug 28, 2025
The Pittsburgh-headquartered nonprofit's executive director, Dallas-based Gina Ford, takes up the newly created top post of the organization, which empowers women across biotech, pharma, and life sciences to lead, engage, and grow at every career stage.
MORE►
by Quincy Preston |
Jul 15, 2025
North Texas' Nanoscope just filed an FDA bid for its gene-agnostic therapy. If approved, it could help restore sight for people with inherited blindness, and potentially millions more with other retinal diseases.
MORE►
by David Seeley |
Jul 15, 2025
The California-based clinical-stage biotech startup is developing therapies to treat serious immunological diseases like atopic dermatitis and vitiligo.
MORE►
Signify Bio co-founders, from left: CEO R.A. Session II and Chief Scientific Officer Daniel Siegwart, Ph.D., of UT Southwestern. {Photos: Taysha Gene Therapies/UTSW]
Dallas’ Signify Bio Launches With Oversubscribed $15M Financing, Partnership With UT Southwestern
by Lance Murray | Jun 5, 2025
Co-founded by Chief Scientific Advisor Daniel J. Siegwart of UT Southwestern and CEO RA Session II, Signify Bio said it harnesses the human body for the production of in situ protein therapeutics. The round was led by Actium Group with participation from the Gates Foundation Strategic Investment Fund, Danaher Ventures LLC, Eli Lilly and Company, and BrightEdge, the American Cancer Society's VC arm.
MORE►
by Lance Murray |
May 8, 2025
Eric Matthews will provide strategic leadership to biopharma business development, and through his executive leadership, support Caris' expanding portfolio of biopharma partnerships, the company said.
MORE►
by Quincy Preston |
Apr 24, 2025
Dallas biotech GenrAb is developing an antibody therapy that aims to protect brain cells under stress—the kind of damage that leads to disability in diseases like MS and ALS. The therapy, found in the spinal fluid of real patients, is now showing promise in animal models and moving toward human trials.
MORE►
by Lance Murray |
Apr 8, 2025
With the new funding, Caris said it has raised $1.86 billion in capital since 2018. Caris will use the raise to bring its science and technologies "to as many patients as possible and further our goal of revolutionizing precision medicine," Founder and CEO David Halbert said.
MORE►
